Search results
Should You Buy Blue Owl Stock for Income at a Low Valuation?
Blue Owl Capital Inc. OWL offers a standout income profile, with a 90 cents per share annual dividend that equates to roughly a 10.65% yield. The company most recently declared a quarterly dividend
BHP Advances Copper Strategy: Can It Unlock Bigger Returns?
BHP Group Limited BHP is reshaping its growth strategy around commodities with durable, long-term demand. Copper sits at the core of this shift, while potash is emerging as a complementary pillar
Do Options Traders Know Something About Afya Stock We Don't?
Investors in Afya Limited AFYA need to pay close attention to the stock based on moves in the options market lately. That is because the June 18, 2026 $2.50 Call had some of the highest implied
Aehr Test Systems (AEHR) is a Great Momentum Stock: Should You Buy?
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell
Here's Why Powell Industries (POWL) is a Great Momentum Stock to Buy
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell
Agenus (AGEN) is a Great Momentum Stock: Should You Buy?
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell
Tokyo Electron Ltd. (TOELY) Is Up 16.55% in One Week: What You Should Know
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell
Here's Why Mitsubishi Electric Corporation (MIELY) is a Great Momentum Stock to Buy
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell
Howmet (HWM) is a Great Momentum Stock: Should You Buy?
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell
HSBC (HSBC) Is Up 6.93% in One Week: What You Should Know
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell
What Makes Pebblebrook Hotel (PEB) a Strong Momentum Stock: Buy Now?
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell
Planet Labs vs. Snowflake: Which AI Data Stock Has an Edge Now?
Artificial Intelligence (AI) is reshaping the software landscape, redefining categories and competitive dynamics. Per The Business Research Company, the AI software market is projected to grow to
3 Reasons Why Growth Investors Shouldn't Overlook Ambev (ABEV)
Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth
Is MasterCard (MA) a Solid Growth Stock? 3 Reasons to Think "Yes"
Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to
KYMR Stock Up as FDA Grants Fast Track Designation to Asthma Drug
Kymera Therapeutics KYMR announced that the FDA has granted a Fast Track designation to its lead candidate, KT-621, for the treatment of moderate-to-severe eosinophilic asthma. KYMR shares rose 4%
J&J Beats Q1 Earnings & Sales Estimates, Raises 2026 Outlook
Johnson & Johnson’s JNJ first-quarter 2026 earnings came in at $2.70 per share, which beat the Zacks Consensus Estimate of $2.67. Earnings declined 2.5% from the year-ago period.
Adjusted earnings
Can TruBridge (TBRG) Run Higher on Rising Earnings Estimates?
TruBridge (TBRG) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since
MRK, Daiichi's BLA for ADC Drug Gets FDA Priority Tag in Lung Cancer
Merck MRK and its Japanese partner Daiichi Sankyo announced that the FDA has accepted the biologics license application (BLA) seeking approval for ifinatamab deruxtecan (I-DXd), a B7-H3-directed DXd
Can Royalty Pharma (RPRX) Keep the Earnings Surprise Streak Alive?
If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Royalty Pharma


